NCT05291156 2024-02-01
CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy
University of Campania Luigi Vanvitelli
Phase 2 Unknown
Clinical Trials
17 trialsNCT03617666 2023-12-12
AVENuE
University College, London
Phase 2 Unknown
NCT03503786 2023-11-13
MITO END-3
National Cancer Institute, Naples
Phase 2 Unknown
NCT03568097 2023-06-02
PAVE
Hellenic Cooperative Oncology Group
Phase 2 Unknown
NCT03774901 2023-04-21
PULSE
Centre Hospitalier Universitaire de Besancon
Phase 2 Unknown
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT04571632 2022-09-14
Luscid
Universitair Ziekenhuis Brussel
Phase 2 Unknown
NCT03491345 2022-08-09
K-Basket, Avelumab, Biomarker-driven, Advanced Solid Tumor
Yonsei University
Phase 2 Unknown
NCT03800953 2021-09-08
The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma
National Taiwan University Hospital
Phase 2 Unknown
NCT04698213 2021-01-06
TIDE-A
Consorzio Oncotech
Phase 2 Unknown
NCT03608046 2020-10-22
AVETUXIRI
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 2 Unknown
NCT03944252 2019-07-26
CARACAS
Gruppo Oncologico del Nord-Ovest
Phase 2 Unknown
NCT03966118 2019-06-03
AIO-STO-0218
Charite University, Berlin, Germany
Phase 2 Unknown
NCT03950362 2019-05-16
PREVERT
Institut Paoli-Calmettes
Phase 2 Unknown
NCT03812796 2019-02-05
EMERGE
Royal Marsden NHS Foundation Trust
Phase 2 Unknown
NCT03512834 2018-07-11
ASAP
Dong-A University Hospital
Phase 2 Unknown
NCT03341845 2018-05-21
Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCC
The Netherlands Cancer Institute
Phase 2 Unknown